Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine.

Abstract

Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. No significant responses were observed in 22 patients with solid tumors. The response rate with betaTGdR alone in acute leukemia was 26% and in combination with Ara-C was 24%. Responses were generally of short duration. Toxicity included myelosuppression, nausea, stomatitis, hyperpigmentation, photosensitivity, and liver function abnormalities.

• Authors: G P Bodey, K B McCredie, J P Whitecar, E M Freireich
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 2 Issue 2 Pg. 199-205 ( 1976) ISSN: 0098-1532 [Print] United States
• PMID: 958161 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Deoxyribonucleosides
• Thionucleosides
• Cytarabine
• Guanosine
• beta-2'-deoxythioguanosine
• Thioguanine
• Deoxyguanosine

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Child
• Child, Preschool
• Cytarabine (adverse effects, therapeutic use)
• Deoxyguanosine (analogs & derivatives)
• Deoxyribonucleosides (therapeutic use)
• Drug Therapy, Combination
• Female
• Guanosine (adverse effects)
• Humans
• Leukemia (drug therapy)
• Leukopenia (chemically induced)
• Male
• Middle Aged
• Neoplasm Metastasis
• Neoplasms (drug therapy)
• Remission, Spontaneous
• Thioguanine (analogs & derivatives, therapeutic use)
• Thionucleosides
• Thrombocytopenia (chemically induced)
• Time Factors